Abstract
BackgroundPembrolizumab (Pb) showed significant benefit in overall survival (OS) and progression-free survival (PFS) versus chemotherapy in patients with untreated metastasic non-small-cell lung cancer (NSCLC) and ≥50% PD-L1 expression. The pembrolizumab-chemotherapy...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have